India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Akero became a wholly owned subsidiary of Novo Nordisk
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
Subscribe To Our Newsletter & Stay Updated
